Treasuries Rally With Japan Bonds as MOF News Boosts Sentiment
Yields on 10-year Treasuries fell by five basis points while those on 30-year bonds slid as much as eight basis points. The moves followed a plunge in long-term Japanese bond yields after the country's finance ministry sent a questionnaire to market participants regarding appropriate issuance amounts. Japan's 20-year yields dropped as much as 19.5 basis points to 2.31%, while 40-year yields declined 25 basis points.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Asian Market Value Picks: 3 Companies That May Be Trading Below Intrinsic Estimates
Amidst global economic uncertainties and fluctuating trade policies, Asian markets have shown resilience, with varying impacts on indices across the region. This environment presents opportunities for discerning investors to explore stocks that may be trading below their intrinsic value, particularly those with strong fundamentals and potential for growth despite external pressures. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xi'an NovaStar Tech (SZSE:301589) CN¥155.51 CN¥309.46 49.7% SpiderPlus (TSE:4192) ¥506.00 ¥997.79 49.3% Ningbo Sanxing Medical ElectricLtd (SHSE:601567) CN¥22.88 CN¥45.72 50% Nanya Technology (TWSE:2408) NT$43.75 NT$87.13 49.8% Nan Ya Printed Circuit Board (TWSE:8046) NT$176.50 NT$350.51 49.6% Insource (TSE:6200) ¥926.00 ¥1843.53 49.8% H.U. Group Holdings (TSE:4544) ¥3254.00 ¥6446.96 49.5% Elan (TSE:6099) ¥850.00 ¥1696.06 49.9% cottaLTD (TSE:3359) ¥441.00 ¥871.25 49.4% Astroscale Holdings (TSE:186A) ¥676.00 ¥1333.68 49.3% Click here to see the full list of 274 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Beijing HyperStrong Technology Overview: Beijing HyperStrong Technology Co., Ltd. designs, develops, integrates, and operates energy storage power stations across China, Europe, North America, and Australia with a market cap of CN¥16.64 billion. Operations: The company's revenue segments include the design, development, integration, and operation of energy storage power stations across its key markets in China, Europe, North America, and Australia. Estimated Discount To Fair Value: 37.2% Beijing HyperStrong Technology is trading at CN¥92.37, significantly below its estimated fair value of CN¥147.06, suggesting it may be undervalued based on cash flows. Its revenue and earnings are forecast to grow over 30% annually, outpacing the Chinese market's growth rates. However, its dividend yield of 1.19% is not well covered by free cash flows. Recent innovations like the HyperBlock M enhance its competitive edge in energy storage solutions through modularity and efficiency improvements. Upon reviewing our latest growth report, Beijing HyperStrong Technology's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of Beijing HyperStrong Technology stock in this financial health report. Shenzhen KSTAR Science and Technology Overview: Shenzhen KSTAR Science and Technology Co., Ltd. operates in the technology sector, focusing on power electronics and renewable energy solutions, with a market cap of CN¥13.86 billion. Operations: Unfortunately, the provided text does not contain specific revenue segment information for Shenzhen KSTAR Science and Technology Co., Ltd. Estimated Discount To Fair Value: 48.5% Shenzhen KSTAR Science and Technology is trading at CN¥23.8, well below its estimated fair value of CN¥46.24, indicating potential undervaluation based on cash flows. The company's revenue is projected to grow 22.3% annually, surpassing the Chinese market's average growth rate. Despite a forecasted earnings growth of 32.4%, profit margins have declined from last year, and the dividend track record remains unstable with recent reductions in payouts for 2024 dividends. The growth report we've compiled suggests that Shenzhen KSTAR Science and Technology's future prospects could be on the up. Click here to discover the nuances of Shenzhen KSTAR Science and Technology with our detailed financial health report. Qingdao Baheal Medical Overview: Qingdao Baheal Medical INC. is involved in the research, development, production, wholesale, and retail of pharmaceutical products across China, the United States, Hong Kong, and the United Kingdom with a market cap of CN¥11.77 billion. Operations: Qingdao Baheal Medical INC. generates revenue through its activities in the research, development, production, wholesale, and retail sectors of pharmaceutical products across several international markets including China, the United States, Hong Kong, and the United Kingdom. Estimated Discount To Fair Value: 18.5% Qingdao Baheal Medical, trading at CN¥22.39, is priced below its fair value estimate of CN¥27.46, reflecting potential undervaluation based on cash flows. Despite a volatile share price recently, earnings are projected to grow significantly at 20.05% annually over the next three years, although this lags behind the broader Chinese market's growth rate. The company affirmed a dividend payout for 2024, which may appeal to income-focused investors amid stable revenue growth projections of 13% per year. In light of our recent growth report, it seems possible that Qingdao Baheal Medical's financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of Qingdao Baheal Medical. Turning Ideas Into Actions Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 271 more companies for you to here to unveil our expertly curated list of 274 Undervalued Asian Stocks Based On Cash Flows. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688411 SZSE:002518 and SZSE:301015. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Australia selects Japan's Mitsubishi Heavy Industries for $6.5B warship deal
WELLINGTON, New Zealand (AP) — Australia said Tuesday it accepted a Japanese company's bid for a lucrative and hotly contested contract to build Australian warships, expected to be worth 10 billion Australian dollars ($6.5 billion). Mitsubishi Heavy Industries' Mogami-class frigate won the deal over rival Germany's MEKO A-200 from Thyssenkrupp Marine Systems. Japan's government lobbied heavily for the deal after missing out on Australia's submarines contract to a French company in 2016. 'This is clearly the biggest defense industry agreement that will ever have been struck between Japan and Australia,' Defense Minister Richard Marles told reporters when he announced the deal Tuesday. 'In fact, it's really one of the biggest defense exports that Japan has ever engaged in.' The fleet of 11 naval vessels will replace Australia's ageing fleet of ANZAC-class ships. Three of the frigates will be built in Japan, with the first scheduled to be operational Australia in 2030, and the remaining eight due for construction in Australia. Australian news outlets reported that the German company's bid had emphasized their vessel's cheaper price and their greater experience building ships abroad. But Pat Conroy, Australia's Minister for Defense Industry, said the Mogami-class frigate was a 'clear winner' when assessed by 'cost, capability and meeting our schedule of delivery.' The vessels have a range of up to 10,000 nautical miles (18,520 kilometers) and 32 vertical launch cells capable of launching long-range missiles. The frigates can operate with a crew of 90, compared to the 170 needed to operate the ANZAC-class ships. Mitsubishi's win was a boon for Japan's defense industry, which has not built naval vessels abroad before. Japan, whose only treaty ally is the United States, considers Australia a semi-ally and has increasingly sought to deepen bilateral military cooperation amid ongoing regional tensions in the disputed South China Sea. 'We welcome the decision by the Australian government as a major step to further elevate Japan's national security cooperation with Australia, which is our special strategic partner,' Japan's Defense Minister Gen Nakatani said Tuesday. Nakatani said co-developing the frigate will allow the two countries to train and operate with the same equipment and further improve operability and efficiency. Japan set up a joint taskforce of government and industry in an effort to win the bid. Australian officials said work on a binding commercial contract with Mitsubishi Heavy Industries and the government of Japan would now begin, with a finalized agreement expected in 2026. They did not say how much each ship would cost or confirm a total figure for the package, citing ongoing negotiations. But Conroy said the government had allowed AU$10 billion for the project over the next 10 years. It forms part of the AU$55 billion that Australia has budgeted for the navy's entire surface combatant fleet during the same period. —- Associated Press writer Mari Yamaguchi contributed from Tokyo. Charlotte Graham-mclay, The Associated Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Glomac Berhad (KLSE:GLOMAC) shareholders have endured a 13% loss from investing in the stock a year ago
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. For example, the Glomac Berhad (KLSE:GLOMAC) share price is down 18% in the last year. That's well below the market decline of 1.8%. The silver lining (for longer term investors) is that the stock is still 1.7% higher than it was three years ago. Furthermore, it's down 12% in about a quarter. That's not much fun for holders. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Unfortunately Glomac Berhad reported an EPS drop of 34% for the last year. The share price fall of 18% isn't as bad as the reduction in earnings per share. So despite the weak per-share profits, some investors are probably relieved the situation wasn't more difficult. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. It might be well worthwhile taking a look at our free report on Glomac Berhad's earnings, revenue and cash flow. What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Glomac Berhad the TSR over the last 1 year was -13%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence! A Different Perspective While the broader market gained around 1.8% in the last year, Glomac Berhad shareholders lost 13% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 5%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Glomac Berhad is showing 2 warning signs in our investment analysis , you should know about... Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
